Press

Welcome to the APEX Press room. Please check back often for updates and news, and don’t hesitate to reach out to media@apexlabs.com with questions or requests.

Apex Labs Granted Approval for 160 Patient Macrodose Multi-Dose Psilocybin Clinical Trial by Health Canada

04.20.23

Cision Canada

Apex Labs Meets Endpoints in First-of-its-Kind Take Home Microdose Psilocybin Clinical Trial

03.29.23

Cision

Apex Labs Granted Approval for 294 Patient Take Home Psilocybin Clinical Trial

01.19.23

Apex Labs Doses First Patient in Take Home Psilocybin Clinical Trial

01.18.23

Apex Labs Granted Approval for North America’s First Take Home Psilocybin Clinical Trial

11.01.22

Health Canada Approves First Special Access Program Requests for Psilocybin

04.08.22

Apex Labs granted phase 2a Clinical Trial Application approval by Health Canada for treatment of PTSD in Veterans

03.08.22

Apex files phase 2a Clinical Trial Application (“CTA”) with Health Canada and announces Series A financing

02.09.22